NCT07317843

Brief Summary

The study is designed to investigate the effects of passive heat therapy on blood vessel health in 40 people (48 enrolled with attrition rate of 20%). Following an extensive set of vascular function tests, participants will engage in either a passive heat therapy intervention for 60 minutes, 4 times a week for 8 weeks, or a placebo intervention at a lower temperature. Seven of the 8 weeks of intervention will occur in the home setting. Vascular function tests will be repeated after the 8 weeks to determine if chronic passive heat stress improved vascular health.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
63mo left

Started Mar 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress2%
Mar 2026Jul 2031

First Submitted

Initial submission to the registry

December 18, 2025

Completed
18 days until next milestone

First Posted

Study publicly available on registry

January 5, 2026

Completed
3 months until next milestone

Study Start

First participant enrolled

March 24, 2026

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2030

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2031

Last Updated

May 5, 2026

Status Verified

April 1, 2026

Enrollment Period

4.7 years

First QC Date

December 18, 2025

Last Update Submit

April 28, 2026

Conditions

Keywords

SCIheat therapyheat stresspassive heatvascular function

Outcome Measures

Primary Outcomes (1)

  • Laser Doppler Flowmetry (LDF)

    Measure of skin blood flow due to local skin heating

    From baseline to end of treatment at 8 weeks

Secondary Outcomes (3)

  • Endothelial Peripheral Arterial Tone (EndoPAT)

    Baseline to end of treatment at 8 weeks

  • Venous Occlusion Plethysmography (VOP)

    From baseline to end of treatment at 8 weeks

  • Cardiac MRI

    Baseline to end of treatment at 8 weeks

Study Arms (2)

HEAT

EXPERIMENTAL

The experimental arm (HEAT) participants undergo an 8-week intervention with 4 weekly passive heat therapy sessions (home based for 7 of 8 weeks) using an electrical heating blanket at a temperature of 42 degrees C.

Other: HEAT - Passive Heat Therapy

SHAM

SHAM COMPARATOR

For participants in SHAM, the heating blankets will be warm (\~34°C) but will not reach a temperature that elevates core temperature. As in the HEAT arm, sessions will be home based for 7 of 8 weeks.

Other: Sham (No Treatment)

Interventions

Participant rests under a heated blanket until the core body temperature has increased at minimum 1 degree Celsius. This usually takes approximately 1 hour. The intervention is performed 4 times a week for a total of 8 weeks.

HEAT

The SHAM intervention participant will rest under a heated blanket that is not set to the degree that the HEAT arm receives. There is no increase of core body temperature.

SHAM

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Participant demonstrates understanding of the study and has provided an appropriately signed and dated informed consent.
  • Participants will be male or female, 18-60 years of age, at the time of Visit 0.
  • Female participants must be non-lactating. Female patients are eligible only if they have a negative pregnancy test throughout the study period (or are postmenopausal). Postmenopausal women taking hormone replacement will be included if they have been on a stable dose for =6 months.
  • Stable SCI (AIS A or B) of longer than 1-year duration.

You may not qualify if:

  • Participants who smoke, or:
  • Uses daily administration of vasoactive medications (e.g., alpha antagonists or agonists or phosphodiesterase inhibitors).
  • Has a current pressure ulcer or skin breakdown.
  • Has an active, uncontrolled, autoimmune or inflammatory disorder
  • Has no history of or current alcohol or substance use disorder
  • Has a history of heat related illness (e.g., heat stroke)
  • Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. This includes, but is not limited to, a clinically relevant medical or surgical history.
  • Is unlikely to cooperate with the requirements of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Audie L Murphy Veterans Memorial Hospital, South Texas Veterans Health Care System

San Antonio, Texas, 78229, United States

RECRUITING

MeSH Terms

Conditions

Spinal Cord InjuriesHyperthermiaHeat Stress Disorders

Interventions

salicylhydroxamic acid

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and InjuriesBody Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Michelle Trbovich, MD

    The University of Texas Health Science Center at San Antonio

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michelle Trbovich, MD

CONTACT

Dean L Kellogg, Jr, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2025

First Posted

January 5, 2026

Study Start

March 24, 2026

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

July 1, 2031

Last Updated

May 5, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations